Ascendis Pharma A/S (Nasdaq: ASND) released promising one-year data from its Phase 3 PaTHway Trial evaluating TransCon PTH, a potential hormone therapy for adults with hypoparathyroidism. 

Hypoparathyroidism is a rare condition characterized by inadequate production of parathyroid hormone, leading to low blood calcium levels and high blood phosphorus levels. These imbalances can result in a variety of symptoms, including muscle cramps, pain, and twitching.

The study demonstrated that treatment with TransCon PTH showed sustained improvements in efficacy and safety over the course of 52 weeks, with similar tolerability to the initial 26-week period. Notably, 95% of patients achieved independence from conventional therapy by Week 52. Patients also reported enhanced disease symptom management and improved quality of life scores throughout the study. 

$ASND closed at $92.35 (-0.12%) on Friday.

Several investment firms have raised their price targets for Adobe Inc. (Nasdaq: ADBE) following the company's upbeat Q2 results. 

Wells Fargo raised their price target from $525 to $600, RBC Capital from $460 to $555, Morgan Stanley from $470 to $510, Mizuho from $450 to $520, and Piper Sandler from $500 to $572. 

With $ADBE closing at $495.18 on Friday, these price target increases suggest a potential upside for the stock, based on the investment firms' views.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)